Nvwa Life Technology  

• Booth: 4631

Guangzhou Nyuwa Life Technology Co., Ltd. is a world-leading innovative company with genome epigenetics research and medical transformation platform. Nyuwa Life aims for providing leading medical testing services for IVF hospitals, reproductive centers and partner organizations. With exclusive epigenetic technologies applied in reproductive medicine field, Nyuwa Life will be able to exterminate infertility and birth defect, and contribute to human’s health and reproduction in the near future.

 Press Releases

• Spectrum Fertility Group Signs Exclusive Contract (Aug 29, 2024)

  Boston, MA – Spectrum Fertility Group Inc. (SFG) has announced a groundbreaking partnership with NVWA Life Technology (NVWA), a global leader in genome epigenetics research and medical transformation platforms. The exclusive contract appoints SFG as the sole provider of NVWA’s innovative products, including the Preimplantation DNA Methylation Detection Kit (PIMS), across all of the Americas.

  This collaboration marks a significant advancement in the field of In Vitro Fertilization (IVF), combining SFG's cutting-edge fertility solutions with NVWA's pioneering genetic technologies. The PIMS kit, which will be at the forefront of this partnership, represents a leap forward in preimplantation genetic diagnosis, offering enhanced accuracy and reliability in detecting DNA methylation patterns that are crucial for successful embryo implantation and development.

  NVWA, renowned for its innovative approaches in genome epigenetics, continues to set the standard in medical transformation platforms. By leveraging its extensive research and development capabilities, NVWA has developed a suite of products that are transforming the landscape of genetic diagnostics and personalized medicine.

  SFG, a leading provider of advanced IVF solutions, is well-positioned to bring these groundbreaking technologies to market. With its established network and expertise in fertility treatments, SFG will ensure that NVWA’s products reach a broad spectrum of healthcare providers and patients throughout North, Central, and South America.

  This partnership is expected to drive significant advancements in the field of reproductive medicine, providing new hope and possibilities for individuals and couples seeking fertility treatments. The integration of NVWA’s PIMS kit into SFG’s offerings will enable more precise and personalized treatment plans, ultimately improving success rates and patient satisfaction.

  For more information about Spectrum Fertility Group Inc. and its services, visit https://www.spectrumfertility.com.

• Spectrum Fertility Executive attends 2024 PGDIS (Aug 29, 2024)

  Spectrum Fertility Group is pleased to announce that our Chief Executive Officer, Angela Prothmann, attended the 2024 Preimplantation Genetic Diagnosis International Society (PGDIS) Conference in Kuala Lumpur, Malaysia. She was accompanied by representatives from our strategic partner, NVWA Life Technology, a leader in cutting-edge epigenetic reproductive health technologies.

  The PGDIS Conference took place from May 5-8, 2024 and is a premier global event that brings together leading scientists, clinicians, and industry professionals in the field of reproductive genetics. The conference serves as a platform for sharing the latest research, advancements, and technologies in preimplantation genetic diagnosis (PGD) and related fields.

  Dr. Liu Jiang, Chief Science Officer, presented NVWA’s latest innovations in embryo screening and fertility treatment optimization called Pre-implantation DNA Methylation Screening (PIMS). His presentation, titled "Advancements in Non-Invasive Preimplantation Genetic Testing," highlighted the company's pioneering epigenetic research and its potential to improve IVF success rates while minimizing risks to both patients and embryos.

  "We are excited to showcase our latest research at the PGDIS Conference," said Dr. Liu. "We are committed to developing advanced genetic testing solutions that are both accurate and non-invasive. This partnership allows us to combine our expertise and deliver better outcomes for patients around the world."

  NVWA Life Technology's CSO, Dr. Liu Jiang, will also be in attendance, underscoring the strong partnership between the two companies. Dr. Liu commented, "Joining forces with Spectrum Fertility Group enables us to leverage our collective knowledge and resources to push the boundaries of what’s possible in reproductive health. We look forward to engaging with the global community after the PGDIS conference and exploring new opportunities for collaboration."

  The Spectrum Fertility Group and NVWA Life Technology team are available for meetings and discussions post conference. Conference attendees are encouraged to visit our website for more information on products and services, and to learn more about latest research findings.

 Products